| Not Yet Recruiting | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event NCT07499128 | National Cancer Institute (NCI) | N/A |
| Recruiting | Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy NCT07390071 | University of Utah | N/A |
| Not Yet Recruiting | Pre-emptive Anakinra for Cytokine Event Reduction NCT06703216 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 / Phase 2 |
| Recruiting | Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study NCT07169487 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab NCT06447376 | Taylor Brooks | Phase 1 |
| Withdrawn | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM NCT06352866 | Jack Khouri, MD | Phase 2 |
| Recruiting | Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy NCT05905328 | CytoAgents, Inc. | Phase 1 / Phase 2 |
| Completed | Jafron Haemoadsorption During Cardiopulmonary Bypass NCT05349669 | Anthea Hospital Bari | Phase 2 |
| Unknown | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy NCT05414162 | University Hospital, Bonn | — |
| Unknown | PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 NCT05096052 | Bioxytran Inc. | Phase 3 |
| Completed | Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Ho NCT04979884 | Alexandria University | Phase 3 |
| Withdrawn | Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection NCT05018975 | Loma Linda University | Phase 2 |
| Active Not Recruiting | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector C NCT04975555 | University of Alabama at Birmingham | Phase 2 |
| Unknown | Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) NCT04048434 | Hannover Medical School | N/A |
| Completed | Safety and Tolerability Study of IV ST266 in COVID-19 Subjects NCT04720378 | Noveome Biotherapeutics, formerly Stemnion | Phase 1 |
| Unknown | Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome NCT04781803 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Completed | Anakinra in the Management of COVID-19 Infection NCT04643678 | Hamad Medical Corporation | Phase 2 / Phase 3 |
| Completed | A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity NCT04150913 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Terminated | Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine NCT04540120 | Olatec Therapeutics LLC | Phase 2 |
| Unknown | Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19 NCT04486521 | King Faisal Specialist Hospital & Research Center | — |
| Terminated | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to NCT04415073 | Syndax Pharmaceuticals | Phase 2 |
| Completed | Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome NCT04403061 | Asociacion para el Estudio de las Enfermedades Infecciosas | — |
| Terminated | Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers NCT04403685 | Beneficência Portuguesa de São Paulo | Phase 3 |
| Completed | Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome NCT04366908 | Maimónides Biomedical Research Institute of Córdoba | Phase 2 |
| Completed | Efficacy and Safety of Itolizumab in COVID-19 Complications NCT04475588 | Biocon Limited | Phase 2 |
| Terminated | Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 NCT04377503 | Hospital Sao Domingos | Phase 2 |
| Completed | Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS NCT04374149 | Prisma Health-Upstate | Phase 2 |
| Completed | Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia NCT04873141 | Shaheed Zulfiqar Ali Bhutto Medical University | — |
| Completed | Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; NCT04485169 | UNICEF | N/A |
| Completed | Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan NCT04492501 | UNICEF | N/A |
| Unknown | Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 NCT04306705 | Tongji Hospital | — |
| Completed | A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy NCT04071366 | Incyte Corporation | Phase 2 |
| Completed | Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resus NCT03685383 | University Hospital Freiburg | N/A |
| Completed | Influence of Cytosorb on Amount of Catecholamine and Mortality in Sepsis NCT04567199 | Medical University Innsbruck | — |
| Terminated | Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies NCT03557749 | Masonic Cancer Center, University of Minnesota | — |
| Completed | Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation NCT03533101 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1 / Phase 2 |
| Completed | Cytokine Removal With CVVHD Compared to CVVH NCT04048525 | Hospital Universitari de Bellvitge | N/A |
| Completed | Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac Surgery NCT01559870 | Thepakorn Sathitkarnmanee | — |
| Completed | Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery NCT01353157 | Khon Kaen University | — |